This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Merus B.V.

Drug Names(s): MCLA158, MCLA 158

Description: MCLA-158 is a bispecific antibody candidate that is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) and epidermal growth factor receptor (EGFR).

MCLA-158 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug